Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Cyxone AB (CYXO) NPV

Sell:6.03 SEK Buy:6.05 SEK Change: 0.03 SEK (0.49%)
Market closed |  Prices as at close on 3 July 2020 | Switch to live prices |
Sell:6.03 SEK
Buy:6.05 SEK
Change: 0.03 SEK (0.49%)
Market closed |  Prices as at close on 3 July 2020 | Switch to live prices |
Sell:6.03 SEK
Buy:6.05 SEK
Change: 0.03 SEK (0.49%)
Market closed |  Prices as at close on 3 July 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cyxone AB is a Sweden-based company, which is primarily focused on specialty pharmaceuticals industry. The Company develops cyclotide drugs for autoimmune and other diseases. The Company's Product T20K is a compound to inhibit pro-inflammatory cytokines such as IL2 and effectively reduce clinical symptoms in an animal model for multiple sclerosis after oral administration. The product T20K, through a pre-clinical program required for clinical studies in multiple sclerosis. The Company's cyclotides technology can be modified, while keeping the core cyclotide drug structure, to introduce a variety of pharmaceutical properties for selected diseases. The Company has acquired the cyclotide patent rights developed by the Medical University of Vienna and the University Medical Center of Freiburg.

Contact details

Address:
Adelgatan 21
MALMO
211 22
Sweden
Telephone:
+ ()
Website:
cyxone.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CYXO
ISIN:
SE0007815428
Market cap:
300.37 million SEK
Shares in issue:
49.08 million
Sector:
Biotechnology
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Bert Junno
    Chairman of the Board
  • Ola Skanung
    Interim Chief Executive Officer, Chief Financial Officer
  • Mikael Lindstam
    Chief Operating Officer, Director
  • Malin Berthold
    Project Manager

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.